Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development · Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes and Other Large Chronic-Disease Markets Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes and Other Large Chronic-Disease Markets · SAN DIEGO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced receipt of an additional $1.5 million funding installment under its multi-year grant agreement in support of development of DARE-LARC1, an investigational long-acting reversible contraceptive based on Daré Bioscience's intelligent drug delivery system (DARE-IDDS) platform. Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. Daré Bioscience believes the DARE-IDDS platform may have potential beyond women's health, including with GLP-1 analogs, anti-obesity medications, hormone therapies for areas such as diabetes, breast cancer, and infertility, and neurologic disease treatments such as for Parkinson’s disease, where long-term dosing and treatment burden are central challenges. In this press release, forward-looking statements include, but are not limited to, statements relating to: DARE-LARC1’s potential as a safe and effective long-acting reversible contraceptive product; continued development of DARE-LARC1; future submission of an IND application for DARE-LARC1; use of the funding installment received and potential for Daré Bioscience to receive additional funding under the grant agreement relating to DARE-LARC1; the potential capabilities of DARE-IDDS as part of a therapeutic product for humans, including storing and delivering discrete doses over periods rang

rare tmem175 mutation drives parkinson s disease pathology by disrupting proton gating and lysosomal acidification

Bambusa Therapeutics’ IPO cash will support its pipeline of bispecific antibodies designed to offer advantages over currently available monoclonal antibodies. Aspen Neuroscience also debuted on the Nasdaq as it prepares for a pivotal test of its Parkinson’s disease cell therapy. Aspen Neuroscience raised $140.6 million in IPO proceeds to support clinical testing of its Parkinson’s disease cell therapy. Late Thursday, the San Diego-based biotech priced its offering of more than 9.3 million shares at $15 each, which was the low end of its targeted price range. “We believe that next-generation therapeutic approaches, particularly bispecific and multi-target biologics that simultaneously modulate complementary and synergistic inflammatory pathways, are necessary to expand responder populations, address the significant unmet medical need, and unify treatment across overlapping disease biology,” the company said in the IPO filing. ... In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable. ... Investor interest in Bambusa’s approach enabled the biotech to increase the deal size by adding more than 1.2 million shares than planned. With the infusion of IPO proceeds, the biotech expects to have enough capital to last into late 2028. Bambusa plans to spend about $90 million for the ongoing development of lead program BBT001, advancing it to the start of a planned Phase 2 test in atopic dermatitis. Bambusa’s two clinical-stage programs trace their origins to Biotheus, a China-based antibody specialist that is now a BioNTech subsidiary following an acquisition last year. BioNTech’s main interest in Biotheus was bispecific antibodies for treating cancer. Bambusa acquired the Biotheus antibodies that became BBT001 and BBT002 and advanced them to the clinic. Bambusa has also identified two additional drug candidates in partnership with the BioNTech subsidiary.

This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Conference in London, as well as new initiatives to accelerate rare disease drug development, promising preclinical data for Duchenne muscular dystrophy, clinical trial progress in advanced Parkinson’s disease, ... This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Conference in London, as well as new initiatives to accelerate rare disease drug development, promising preclinical data for Duchenne muscular dystrophy, clinical trial progress in advanced Parkinson’s disease, and a potential new drug target for breast cancer. The DDW Fall 2026 issue examines precision therapies for Parkinson's Disease, what the resurgence of neuroscience means for drug discovery and why cancer vaccines depend on DNA synthesis. Other features in the Fall issue include: From investment to innovation - why we've launched a new event series The three generations of obesity medications Rethinking paediatric oncology treatments Read More ScionxBio, a preclinical-stage biotechnology company developing next-generation mRNA therapeutics, has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialise extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio’s AI-driven platform. Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell Science

October 30, 2026 08:32 ET | Source: Daré Bioscience, Inc. Daré Bioscience, Inc · Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes and Other Large Chronic-Disease Markets · SAN DIEGO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced receipt of an additional $1.5 million funding installment under its multi-year grant agreement in support of development of DARE-LARC1, an investigational long-acting reversible contraceptive based on Daré Bioscience's intelligent drug delivery system (DARE-IDDS) platform. Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. Daré Bioscience believes the DARE-IDDS platform may have potential beyond women's health, including with GLP-1 analogs, anti-obesity medications, hormone therapies for areas such as diabetes, breast cancer, and infertility, and neurologic disease treatments such as for Parkinson’s disease, where long-term dosing and treatment burden are central challenges. In this press release, forward-looking statements include, but are not limited to, statements relating to: DARE-LARC1’s potential as a safe and effective long-acting reversible contraceptive product; continued development of DARE-LARC1; future submission of an IND application for DARE-LARC1; use of the funding installment received and potential for Daré Bioscience to receive additional funding under the grant agreement relating to DARE-LARC1; the potential capabilities of DARE-IDDS as part of a therapeutic product for humans, including storing and delivering discrete doses over periods rang